{"title":"双膦酸盐在转移性骨病中的应用","authors":"R A Hubner, S J Houston","doi":"10.12968/hmed.2005.66.7.18388","DOIUrl":null,"url":null,"abstract":"<p><p>Bisphosphonates already have an established role in the management of the skeletal complications of metastatic bone disease. The development of new, highly potent compounds has led to investigation into their use as preventive agents in the adjuvant setting. The aim of the paper is to evaluate the evidence for their use in prevention and treatment.</p>","PeriodicalId":79637,"journal":{"name":"Hospital medicine (London, England : 1998)","volume":"66 7","pages":"414-9"},"PeriodicalIF":0.0000,"publicationDate":"2005-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.12968/hmed.2005.66.7.18388","citationCount":"8","resultStr":"{\"title\":\"Bisphosphonates' use in metastatic bone disease.\",\"authors\":\"R A Hubner, S J Houston\",\"doi\":\"10.12968/hmed.2005.66.7.18388\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Bisphosphonates already have an established role in the management of the skeletal complications of metastatic bone disease. The development of new, highly potent compounds has led to investigation into their use as preventive agents in the adjuvant setting. The aim of the paper is to evaluate the evidence for their use in prevention and treatment.</p>\",\"PeriodicalId\":79637,\"journal\":{\"name\":\"Hospital medicine (London, England : 1998)\",\"volume\":\"66 7\",\"pages\":\"414-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.12968/hmed.2005.66.7.18388\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital medicine (London, England : 1998)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12968/hmed.2005.66.7.18388\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital medicine (London, England : 1998)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12968/hmed.2005.66.7.18388","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bisphosphonates already have an established role in the management of the skeletal complications of metastatic bone disease. The development of new, highly potent compounds has led to investigation into their use as preventive agents in the adjuvant setting. The aim of the paper is to evaluate the evidence for their use in prevention and treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
